Ocular Therapeutix (OCUL) was added to several Russell value and small cap benchmarks on June 27, 2026, a change that can influence trading activity as index trackers adjust their holdings.

The Russell index additions come after a sharp recent rebound in Ocular Therapeutix, with a 30 day share price return of 26.59% and a 90 day share price return of 11.08%, even though the year to date share price return is still down 12.61% and the 1 year total shareholder return is down 4%, while the 3 year total shareholder return sits at about 2.2x.

If you are looking beyond Ocular Therapeutix, this could be a good moment to see what else is moving in healthcare and biotech by checking out 40 healthcare AI stocks

After a sharp rebound, loss-making Ocular Therapeutix now trades at a much higher share price and at a wide gap to analyst targets. This raises the question: does the current setup still tilt the risk-reward balance in favour of buyers or not?

Most Popular Narrative: 60.3% Undervalued

At a last close of $10.33 versus a widely followed fair value of $26, the current narrative on Ocular Therapeutix leans heavily on long term retinal potential and aggressive growth assumptions.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see what is baked into that $26 fair value for Ocular Therapeutix? The narrative leans on rapid revenue expansion, margin repair, and a future earnings multiple that assumes strong investor confidence. Curious which specific growth and profitability paths need to line up to keep that story intact?

Result: Fair Value of $26 (UNDERVALUED)

However, the bullish Ocular Therapeutix story could unravel if AXPAXLI stumbles in clinical or regulatory review, or if extended R&D spending drives further shareholder dilution.

Another View: Ocular Therapeutix Through a Sales Multiple Lens

The SWS DCF model points to Ocular Therapeutix trading around 90.3% below an estimated future cash flow value of about $106 per share, yet the current P/S ratio of 43.5x is far above the US Pharmaceuticals industry at 6.6x, the peer average at 6.5x, and a fair ratio of 0.2x. This leaves you weighing a wide gap between growth hopes and multiple risk.

Next Steps

Given the mix of optimism and concern around Ocular Therapeutix, it can be helpful to act promptly and review the numbers yourself, including the underlying assumptions behind 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Ocular Therapeutix?

If Ocular Therapeutix has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot other opportunities that might suit your style.

• Target potential value opportunities by checking stocks that appear mispriced on fundamentals through the 45 high quality undervalued stocks.
• Prioritize resilience by focusing on companies with strong finances using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for potential future standouts by scanning the market with the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.